Zedge (AMEX:ZDGE) Bolsa

Zedge

Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.

Zedge Inc

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday.
Shares of lululemon athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) fell sharply in today's pre-market trading after the company cut its FY25 GAAP EPS guidance <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45803189/lululemon-q1-earnings-revenue-beat-eps-in-line-shares-tumble-on-weaker-earnings-forecast">below estimates</a>.
Lululemon reported first-quarter revenue of $2.37 billion, beating the consensus estimate of $2.36 billion, according to Benzinga Pro.
The company lowered its full-year earnings forecast to $14.58 to $14.78 per share, down from prior guidance of $14.95 to $15.15 per share. Analysts are anticipating full-year earnings of $14.88 per share.
lululemon athletica shares dipped 20.9% to $261.60 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) shares dipped 34.7% to $20.00 in pre-market trading after falling 4% on Thursday.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) fell 19.2% to $75.10 in pre-market trading. DocuSign posted better-than-expected first-quarter results and announced a $1 billion increase to its share purchase program. Docusign said it sees second-quarter revenue in a range of $777 million to $781 million, versus the $774.75 million estimate. The company raised its fiscal 2026 revenue outlook to a range of $3.15 billion to $3.16 billion, versus the $3.14 billion estimate.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) fell 17.2% to $4.47 in pre-market trading after gaining 12% on Thursday.</li>
<li>Liminatus Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) dipped 15.8% to $20.70 in pre-market trading. Liminatus Pharma shares jumped around 94% on Thursday after the company announced it regained Nasdaq compliance.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) fell 13.5% to $40.90 in today's pre-market trading following first-quarter results.</li>
<li>ServiceTitan, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) dipped 10.8% to $102.11 in pre-market trading after the company posted quarterly results.</li>
<li>Petco Health and Wellness Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) declined 10.2% to $3.25 in pre-market trading after the company reported worse-than-expected first-quarter sales results.</li>
<li>Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) fell 8.6% to $32.99 in pre-market trading after the company cut its FY26 adjusted EPS guidance below estimates.</li>
<li>Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) fell 3.6% to $59.78 in pre-market trading.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BRZE

DOCU

LIMN

LULU

TCOM

TTAN

VERA

WOOF

Lululemon Cuts Earnings Forecast, Joins DocuSign, Samsara And Other Big Stocks Moving Lower In Friday's Pre-Market Session

WIIM

RKLB

Rocket Lab shares are trading higher after the company announced the launch window for its next mission, 'The Mountain God Guards,' for the Institute for Q-shu Pioneers of Space.

Founders hear &#8220;no&#8221; a lot. Sometimes it&#8217;s a quick pass, sometimes it&#8217;s silence after a promising call. But in venture, saying &#8220;no&#8221; is part of the job &#8211; most investors back fewer than <a href="https://www.forbes.com/sites/hollyeve/2020/07/06/venture-capital-is-not-the-funding-reality-of-most-startups-heres-what-is/">1% of the startups</a> they meet. That doesn&#8217;t mean your company is bad. It just means that, from the investor&#8217;s perspective, something didn&#8217;t click.
At P2S, we review thousands of startups each year. We pass on most of them &#8211; not because they&#8217;re not smart or ambitious, but because venture capital is about fit, trust, and conviction. Here are the real reasons we (and other VCs) say no, and what you, as a founder, can take away from that.
<h3 class="wp-block-heading">1. Not a Portfolio Fit</h3>
Sometimes it's just not the kind of company we invest in. You might be building something brilliant in deeptech or consumer goods &#8211; but if our focus is AI SaaS or fintech, we'll pass. It's not personal. Good investors stay disciplined in their thesis. That also includes stage: a pre-product idea pitched to a growth-stage fund is likely a mismatch.
What you can control: Target the right funds. Look at what they've backed. If your company looks nothing like the rest of the portfolio, you might be knocking on the wrong door. It also helps to reference why you're a potential fit in your outreach &#8211; a short line that says "I saw you backed X, which solves a similar problem in a different market" can go a long way.
<h3 class="wp-block-heading">2. Founder-Investor Misalignment</h3>
Venture is a long-term relationship. We need to trust the founder and believe we can work together through the hard days. If there's poor communication, defensiveness, or a sense that the founder isn't being fully transparent &#8211; we back away.
Sometimes there's just no chemistry. You might remind a partner of a painful previous deal. Or the values don't line up. Again, it's not always rational, but trust and transparency matter.
What you can control: Be honest, clear, and direct. Investors are humans &#8211; we remember founders who can take feedback, ask thoughtful questions, and don't pretend to know everything. Sometimes it's as simple as feeling like the founder is open to partnership, not just capital.
<h3 class="wp-block-heading">3. Unclear Story</h3>
You may be solving something important. But if we can't understand what you do, why it matters, and why you'll win &#8211; we pass. A confused investor never writes a check. If we don't see the unique insight, or how this becomes a big company, it's a no.
What you can control: Your narrative. What's the problem? Why now? Why you? Say it without buzzwords. Founders who can explain their business in 30 seconds &#8211; and get us excited &#8211; have a real edge. Clarity shows depth. And when a story resonates, it gets repeated internally &#8211; you want the junior investor you pitched to be able to pitch it again in a partner meeting (we have ours each Wednesday).
<h3 class="wp-block-heading">4. Timing Is Off</h3>
You might be too early &#8211; before customers are ready to pay. Or too late &#8211; in a crowded space with no clear wedge. Or maybe you're raising more than makes sense for your stage. If we can't connect your timing to a compelling opportunity, we pass.
What you can control: Show that now is the moment. Back it with signals: market shifts, early traction, urgency. Help us believe this isn't a "someday" business. If you are early, show a clear roadmap &#8211; what will you achieve with this round, and what milestones will unlock the next one?
<h3 class="wp-block-heading">5. Risk or Red Flags</h3>
Sometimes the risk isn't worth it. A messy cap table, unresolved legal issues, or high burn without progress are red flags. If something feels off &#8211; and the founder isn't upfront &#8211; that's often a deal breaker.†
What you can control: Be transparent. Acknowledge risks, explain your plan to fix them. Most VCs can live with risk &#8211; they just hate surprises (unless positive). If your burn is high, show what it's buying you. If your cap table has issues, show that you're cleaning it up. Proactive communication is a trust builder.
Why Feedback Feels Vague
You've probably heard phrases like "too early," "not the right fit," or "we're passing for now." They're frustrating. But here's the truth: investors don't always want to give tough feedback. It's uncomfortable, and it can burn bridges. So we default to polite ambiguity.
Still, if you listen carefully, you'll find patterns. If three funds say you're too early, maybe you need more traction. If they don't get your vision, maybe the story needs work. Sometimes feedback isn't even about you &#8211; it's about internal dynamics, shifts in focus, or the partner not getting support.
What you can do: Ask. Even if the answer is vague, the way it&#8217;s said tells you something. And if you get consistent signals, use that data. Iterate. Many great startups started with a dozen rejections before something clicked.
<h3 class="wp-block-heading">Regret Works Both Ways</h3>
Yes, we all feel disappointed when an investment doesn't work out. But in venture, the deeper regret usually isn't about the losses &#8211; it's about the deals we passed on that turned into generational companies. Those are the ones you never forget.
No investor gets every decision right. That's why we focus on signals, trust, and pattern recognition. But we're also wrong, often. A no today doesn't mean a no forever. We've said yes on the second or third pitch &#8211; once the story got clearer, or the timing aligned.
<h3 class="wp-block-heading">Final Thoughts</h3>
You will hear &#8220;no.&#8221; Many times. That doesn't mean you're not onto something. Focus on what you can control &#8211; the clarity of your story, the strength of your team, your speed of execution, and the way you show up in the room.
Build momentum, show progress, and treat every pass as part of the game, not the end of it. Great founders don't get discouraged &#8211; they get sharper. They learn, adjust, and keep going.
At <a href="http://p2s.vc">P2S</a>, we're always looking for bold founders building with urgency, determination and honesty. If that's you &#8211; pitch us. We'd love to hear your story.

Opinion

Startups

General

Why VCs Say No: Key Insights For Founders

RBRK

Rubrik shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 guidance above estimates. Also, the company raised its FY26 guidance above estimates.

Mosaic shares are trading lower after the company cut its Q2 phosphate sales and FY25 output.

Casey&#8217;s General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) will release its fourth-quarter financial results after the <a href="https://www.benzinga.com/quote/CASY/earnings">closing bell on Monday, June 9.</a>
Analysts expect the company to report quarterly earnings at $1.95 per share, down from $2.34 per share in the year-ago period. Casey&#8217;s projects quarterly revenue of $3.95 billion, compared to $3.6 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 11, Keybanc analyst Bradley Thomas initiated coverage of Casey&#8217;s with an Overweight rating and announced a price target of $500.
With the recent buzz around Casey&#8217;s, some investors may be eyeing potential gains from the company's dividends too. As of now, Casey&#8217;s offers an annual dividend yield of 0.45%, which is a quarterly dividend amount of 50 per share ($2.00 a year).
To figure out how to earn $500 monthly from Casey&#8217;s, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Casey&#8217;s $2.00 dividend: $6,000 / 2.00 = 3,000 shares.
So, an investor would need to own approximately $1,337,070 worth of Casey&#8217;s, or 3,000 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $2.00 = 600 shares, or $267,414 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
CASY Price Action: Shares of Casey&#8217;s fell by 0.6% to close at $445.69 on Thursday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

Earnings

Long Ideas

Dividends

CASY

How To Earn $500 A Month From Casey's Stock Ahead Of Q4 Earnings

Telsey Advisory Group analyst Dana Telsey maintains Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) with a Market Perform and maintains $6 price target.

Price Target

Analyst Ratings

CURV

Telsey Advisory Group Maintains Market Perform on Torrid Holdings, Maintains $6 Price Target

Samsara shares are trading lower. The company reported Q1 financial results.

ServiceTitan shares are trading lower after the company reported worse-than-expected Q1 sales results.

Telsey Advisory Group analyst Dana Telsey maintains PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) with a Outperform and maintains $90 price target.

Telsey Advisory Group Maintains Outperform on PVH, Maintains $90 Price Target

DocuSign shares are trading lower. The company reported Q1 financial results

Lululemon Athletica shares are trading lower after the company reported Q1 financial results and issued its Q2 GAAP EPS results below estimates. Also, the company cut its FY25 GAAP EPS guidance below estimates.

Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing.
DENVER, CO / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 6, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYTU#NASDAQ">AYTU</a>), a pharmaceutical company focused on commercializing novel therapeutics, today announced the pricing of an upsized public offering of 9,600,000 shares of common stock (or prefunded warrants in lieu thereof) at an effective public offering price of $1.50. In addition, Aytu has granted the underwriters a 30-day option to purchase up to an additional 1,440,000 shares of its common stock at the public offering price.
The offering is expected to close on or about June 9, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds to the Company, before deducting underwriters' fees and other offering expenses, are expected to be approximately $14.4 million. The Company intends to use the net proceeds of this offering for general corporate purposes, working capital and general and administrative expenses, and to execute on a transaction that will enable the Company to exclusively commercialize EXXUA&#x2122; (gepirone) extended-release tablets, a novel, branded, FDA-approved treatment for major depressive disorder in the United States.

AYTU

Aytu BioPharma Prices Upsized Public Offering Of 9.60M Shares At Effective Public Offering Price Of $1.50

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and maintains $13 price target.

Telsey Advisory Group Maintains Market Perform on Guess, Maintains $13 Price Target

AVGO

Broadcom shares are trading lower. The company reported Q2 financial results.

Small Cap Consumer Research analyst Eric Beder reiterates Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and maintains $23 price target.

Reiteration

Small Cap Consumer Research Reiterates Buy on Guess, Maintains $23 Price Target

DeFi Development Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company" or "DeFi Dev Corp."), the first US public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced a strategic partnership with Drift Protocol, the leading decentralized derivatives exchange on Solana with $1B in deposits.
As part of the collaboration, Drift intends to integrate dfdvSOL, a liquid staking token (LST) staking to the DeFi Dev Corp. validator, into Drift's borrow/lend market. This integration expands the utility of dfdvSOL into Solana, offering market participants new ways to access rewards while holding a reward-generating, SOL position staked with DeFi Dev Corp.

DFDV

DeFi Development Partners With Drift Protocol; Drift Intends To Integrate dfdvSOL, LST Staking To Defi Dev Corp. Validator, Into Drift's Borrow/Lend Market

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/06/05/final-trades-ulta-disney-gap-and-the-slv.html">Halftime Report Final Trades</a>,&#8221; Stephanie Link, chief investment strategist and portfolio manager at Hightower, said The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) is down 33% in a week and recommended using the weakness to buy the stock. The stock trades at 9.7 times and has a dividend yield of 3.1%. 
Link said the clothing retailer reported a robust quarter that gained market share, and praised the new management as &#8220;phenomenal.&#8221;
Gap reported quarterly earnings of 51 cents per share on May 29, beating the consensus estimate of 45 cents. Quarterly revenue came in at $3.46 billion, beating the Street estimate of $3.42 billion.
Cerity Partners&#8217;s Jim Lebenthal said The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) has been in the $115 range. He expects the stock to break above $120.
As per the recent news, on June 4, Walt Disney lost its legal effort to prevent longtime executive Justin Connolly from leaving the company to join Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) YouTube.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Bill Baruch, founder and President of both Blue Line Capital and Blue Line Futures, picked iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>), saying silver reached the highest level since 2012.
On the earnings front, Westinghouse Air Brake, on April 23, reported better-than-expected first-quarter adjusted EPS results and raised its FY25 adjusted EPS guidance.
Brian G. Belski of BMO Capital Markets named Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) as his final trade.
Lending support to his choice, Ulta Beauty, on May 29, reported quarterly earnings of $6.70 per share, which beat the consensus estimate of $5.77 per share Quarterly revenue of $2.85 billion beat the Street estimate of $2.79 billion.
Price Action:
<ul class="wp-block-list">
<li>Gap shares gained 2.6% to close at $21.58 on Thursday.</li>
<li>Disney fell 0.9% to close at $112.53 on Thursday.</li>
<li>iShares Silver Trust gained 3.5% during the session.</li>
<li>Ulta Beauty shares rose 0.3% to settle at $467.04.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Image: Shutterstock

Media

GOOG

GOOGL

ULTA

Gap, Disney, Ulta Beauty And More On CNBC's 'Final Trades'

On CNBC's &#8220;Mad Money Lightning Round,&#8221;<a href="https://www.benzinga.com/topic/jim-cramer"> Jim Cramer recommended </a>buying RELX PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RELX#NYSE">RELX</a>).
Supporting his view, Barclays analyst Julien Roch, on March 14, upgraded RELX from <a href="https://www.benzinga.com/quote/RELX/analyst-ratings">Equal-Weight to Overweight</a>.
&nbsp;&#8220;I personally would not own Altria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>),&#8221; Cramer said.
On the earnings front, the company reported a first-quarter FY25 sales decline of 5.7% year-on-year to $5.26 billion on April 29, beating the analyst consensus estimate of $4.62 billion. Adjusted EPS of $1.23 beat the consensus estimate of $1.18.
Cramer said he would not recommend Lincoln National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) and recommended going with Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>).
As per recent news, Lincoln Financial and Bain Capital announced on June 5 the closing of an equity capital raise and the launch of a long-term strategic partnership.
When asked about EHang Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>), he said, &#8220;I'm not going to really want to do a lot of China right now.&#8221;
On the earnings front, EHang Holdings posted an adjusted loss of 6 cents per share on May 26, compared to a loss of 2 cents per share the previous year.
Price Action:
<ul class="wp-block-list">
<li>RELX shares fell 1% to settle at $53.80 on Thursday.</li>
<li>Altria gained 0.1% to settle at $59.39 on Thursday.</li>
<li>Lincoln National shares rose 0.4% to close at $32.81.</li>
<li>EHang shares fell 1.6% to settle at $16.05 during the session.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45790405/top-2-defensive-stocks-that-are-ticking-portfolio-bombs">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo: Shutterstock

RELX

Cramer Says He's 'Not Going To Really Want To Do A Lot Of China Right Now'

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline
83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS)
9.1 point average rVCSS improvement among the clinically meaningful benefit cohort
Subjects experienced a median 74% improvement in leg pain
Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators
A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025
Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - <a href="https://us02web.zoom.us/webinar/register/WN_ZCYHR5WuRmO68za9hKH3iQ">Access the Webcast Here</a>
IRVINE, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 6, 2025 / enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the <a href="https://pr.report/b7xj">Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25)</a> being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a <a href="https://pr.report/b7xk">live webcast</a> to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below).
Key interim two-year follow-up data being presented at VAM25 include:
83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).
9.1 point average rVCSS improvement among the responder cohort.
A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).
Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size.
Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).
Among the subjects (n=30), a 100% valve patency rate.
All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases.

NVNO

enVVeno Medical To Present Interim Two-Year Follow-Up Data On 42 Subjects From 75 Person VenoValve U.S. Pivotal Trial At SVS VAM25

Press Releases

Zedge To Report First Fiscal Quarter 2025 Results

Zedge Announces First Quarter Fiscal 2025 Results

Zedge Announces GuruShots Restructuring to Improve Profitability and Position Itself for Long-term Growth

Zedge Increases Cost Reduction Efforts to a Targeted $4 Million Annually

Zedge To Report Second Fiscal Quarter 2025 Results

Zedge Announces Second Quarter Fiscal 2025 Results

Events

Zedge to Present at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub

Zedge To Report Third Fiscal Quarter 2025 Results

Zedge to Participate in the "2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow" Virtual Conference Presented by Maxim Group

Zedge Launches DataSeeds.AI, a Content Marketplace for AI Training Sets

ZDGE

Antelope Enterprise Holdings Limited - Class A Ordinary Shares

Antelope Ent Hldgs

The Arena Group Holdings, Inc. Common Stock

Arena Group Holdings

BuzzFeed

Cheer Holding, Inc. - Class A Ordinary Share

Cheer Holding

DHI Group

Fangdd Network Group Ltd. - Class A Ordinary Shares

Fangdd Network Group

Phoenix New Media Limited American Depositary Shares, each representing 48 Class A ordinary shares.

Comments

Zedge

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL